Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, engaged in transactions involving the company's common stock on August 13 and 14, 2024.
• These transactions involved the exercise of stock options at a price of $129.49 per share and subsequent sales of the acquired shares at varying prices ranging from approximately $319 to $338.
• The exercises and sales were conducted under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
• On both August 13 and 14, 3,600 stock options were exercised.
• The trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
• Following these transactions, Rothblatt directly owns 130 shares of common stock.
• Rothblatt also indirectly owns shares through various family trusts, including 166 shares by spouse, 245,909 shares by trust, 28,170 shares by trust, 324,518 shares by trust and 45,596 shares by trust.
• After the transactions, Rothblatt directly owns 25,469 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy; potential negative perception due to stock sales is balanced by the transparency of the 10b5-1 plan.

Positives

• The use of a pre-arranged 10b5-1 trading plan suggests that the transactions were planned and not based on insider information.
• The CEO's continued indirect ownership through family trusts indicates a long-term commitment to the company.

Negatives

• The sale of shares by the CEO, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• Continued sales under the 10b5-1 plan could exert downward pressure on the stock price.
• Market volatility could impact the effectiveness of the trading plan.

Future Outlook

The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of 723,869 stock options expiring on December 31, 2024; future transactions will depend on the plan's execution and market conditions.

Industry Context

Executive stock transactions are common and closely monitored in the pharmaceutical industry; 10b5-1 plans are a standard tool for executives to manage their stock holdings while avoiding insider trading concerns.

Comparison to Industry Standards

• Executive compensation practices, including stock options and trading plans, are common across publicly traded pharmaceutical companies.
• Companies like Amgen, Gilead Sciences, and Johnson & Johnson also utilize similar mechanisms for executive stock transactions.
• The size and frequency of these transactions are generally in line with industry norms for companies of United Therapeutics' size and market capitalization.

Stakeholder Impact

• Potential impact on shareholders due to stock sales, although mitigated by the pre-arranged nature of the transactions.
• No immediate impact on employees, customers, suppliers, or creditors is apparent.

Next Steps

• Continued monitoring of stock transactions under the 10b5-1 trading plan.
• Potential future Form 4 filings as the plan continues to execute.

Key Dates